Erika Berman-Rosenzweig

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9502854/publications.pdf

Version: 2024-02-01

142 papers 9,885 citations

41344 49 h-index 96 g-index

148 all docs 148 docs citations

148 times ranked 7387 citing authors

#	Article	IF	Citations
1	Characteristics and prognostic significance of right heart remodeling and tricuspid regurgitation after pulmonary endarterectomy. Journal of Thoracic and Cardiovascular Surgery, 2024, 167, 658-667.e7.	0.8	2
2	Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry. European Respiratory Journal, 2022, 59, 2003337.	6.7	43
3	Early Mobilization during Extracorporeal Membrane Oxygenation for Cardiopulmonary Failure in Adults: Factors Associated with Intensity of Treatment. Annals of the American Thoracic Society, 2022, 19, 90-98.	3.2	35
4	Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Annals of the American Thoracic Society, 2022, 19, 227-237.	3.2	16
5	Cardiac Catheterization and Hemodynamics in a Multicenter Cohort of Children with Pulmonary Hypertension. Annals of the American Thoracic Society, 2022, 19, 1000-1012.	3.2	6
6	Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Realâ€world experience. Pediatric Pulmonology, 2022, 57, 724-733.	2.0	7
7	Building a Dedicated Pediatric Pulmonary Hypertension Program: A Consensus Statement from the Pediatric Pulmonary Hypertension Network. Pulmonary Circulation, 2022, 12, e12031.	1.7	1
8	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.6	17
9	Impact of sex, race and socioeconomic status on survival after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	3
10	Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 229-237.	3.2	18
11	Left Pulmonary Artery Ligation and Chronic Pulmonary Artery Banding Model for Inducing Right Ventricularâ€"Pulmonary Hypertension in Sheep. ASAIO Journal, 2021, 67, e44-e48.	1.6	6
12	A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension: Early experience in adolescents and adults. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1438-1446.e2.	0.8	37
13	Congenital Heart Disease-Associated Pulmonary Hypertension. Clinics in Chest Medicine, 2021, 42, 9-18.	2.1	15
14	Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine, 2021, 13, 80.	8.2	43
15	Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1472-1487.	5.6	68
16	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulmonary Circulation, 2021, 11, 1-10.	1.7	17
17	A Large Animal Model for Pulmonary Hypertension and Right Ventricular Failure: Left Pulmonary Artery Ligation and Progressive Main Pulmonary Artery Banding in Sheep. Journal of Visualized Experiments, 2021, , .	0.3	5
18	ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest, 2021, 160, 297-306.	0.8	6

#	Article	IF	CITATIONS
19	Lung transplantation disparities based on diagnosis for patients bridging to transplant on extracorporeal membrane oxygenation. Journal of Heart and Lung Transplantation, 2021, 40, 1641-1648.	0.6	10
20	Abstract 10753: Exercise-Induced ECG Changes Predict Adverse Outcomes in Pulmonary Hypertension. Circulation, 2021, 144, .	1.6	0
21	Commentary: Keeping the reversed Potts shunt reversed: Insights from the fourth dimension. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.8	1
22	Author rebuttal to response regarding "Letter to the Editor regarding â€~Could pulmonary arterial hypertension patients be at lower risk from severe COVIDâ€19?'â€. Pulmonary Circulation, 2020, 10, 1-2.	1.7	5
23	Chronic Thromboembolic Pulmonary Hypertension in a Child With Sickle Cell Disease. Frontiers in Pediatrics, 2020, 8, 363.	1.9	4
24	Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. Journal of Pediatrics, 2020, 223, 164-169.e1.	1.8	9
25	Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatric Research, 2020, 88, 850-856.	2.3	6
26	Targeted Therapy for Pulmonary Hypertension in Premature Infants. Children, 2020, 7, 97.	1.5	9
27	A rare childhood case of Behcet's disease and chronic thromboembolic pulmonary hypertension. Journal of Cardiac Surgery, 2020, 35, 1669-1672.	0.7	5
28	Right Ventricular Clot in Transit in COVID-19. JACC: Case Reports, 2020, 2, 1391-1396.	0.6	22
29	SARS-CoV-2 Infection in Patients with Down Syndrome, Congenital Heart Disease, and Pulmonary Hypertension: Is Down Syndrome a Risk Factor?. Journal of Pediatrics, 2020, 225, 246-248.	1.8	27
30	Cardiac workup and monitoring in hospitalised children with COVID- 19. Cardiology in the Young, 2020, 30, 907-910.	0.8	4
31	Comprehensive Diagnostic Evaluation of Cardiovascular Physiology in Patients With Pulmonary Vascular Disease. Circulation: Heart Failure, 2020, 13, e006363.	3.9	27
32	Could pulmonary arterial hypertension patients be at a lower risk from severe COVIDâ€19?. Pulmonary Circulation, 2020, 10, 1-2.	1.7	45
33	Intravascular Ultrasound Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension (TROPHY1). JACC: Cardiovascular Interventions, 2020, 13, 989-999.	2.9	47
34	Care of patients with pulmonary arterial hypertension during the coronavirus (COVIDâ€19) pandemic. Pulmonary Circulation, 2020, 10, 1-7.	1.7	50
35	Abstract 15029: Atrial Arrhythmias and Pulmonary Hypertension Across Wsph Groups. Circulation, 2020, 142, .	1.6	0
36	Childhood Pulmonary Arterial Hypertension. , 2019, , 556-579.e4.		0

#	Article	lF	Citations
37	Response. Chest, 2019, 156, 187-188.	0.8	O
38	Extracorporeal life support bridge for pulmonary hypertension: A high-volume single-center experience. Journal of Heart and Lung Transplantation, 2019, 38, 1275-1285.	0.6	27
39	Racial and Ethnic Differences in Pediatric Pulmonary Hypertension: An Analysis of the Pediatric Pulmonary Hypertension Network Registry. Journal of Pediatrics, 2019, 211, 63-71.e6.	1.8	22
40	Acute vasoreactivity testing in pediatric idiopathic pulmonary arterial hypertension: an international survey on current practice. Pulmonary Circulation, 2019, 9, 1-9.	1.7	7
41	Response: Still puzzling about a clear definition of pulmonary arterial hypertension in newborns. European Respiratory Journal, 2019, 53, 1900135.	6.7	3
42	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine, the, 2019, 7, 227-238.	10.7	122
43	Therapy for Pulmonary Arterial Hypertension in Adults. Chest, 2019, 155, 565-586.	0.8	216
44	Sildenafil Use in Children with Pulmonary Hypertension. Journal of Pediatrics, 2019, 205, 29-34.e1.	1.8	58
45	Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. European Respiratory Journal, 2019, 53, 1801916.	6.7	399
46	PH Grand Rounds: Eisenmenger Syndrome: When Less Is More. Advances in Pulmonary Hypertension, 2019, 18, 33-36.	0.1	0
47	The Left Ventricle in Congenital Diaphragmatic Hernia: Implications for the Management of Pulmonary Hypertension. Journal of Pediatrics, 2018, 197, 17-22.	1.8	79
48	Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. Circulation Genomic and Precision Medicine, 2018, 11, e001887.	3.6	104
49	Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Medicine, 2018, 44, 717-729.	8.2	230
50	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174.	5 . 6	17
51	Eisenmenger Syndrome and Pregnancy: Novel ECMO Configuration as a Bridge to Delivery and Recovery Utilizing a Multidisciplinary Team. ASAIO Journal, 2018, 64, e8-e10.	1.6	13
52	Eisenmenger Syndrome in Pregnancy: When Is It Time for ECMO?: A Case Report. A&Amp A Practice, 2018, 11, 270-272.	0.4	9
53	Increasing Opportunity for Lung Transplant in Interstitial Lung Disease With Pulmonary Hypertension. Annals of Thoracic Surgery, 2018, 106, 1812-1819.	1.3	30
54	Loss-of-Function <i>ABCC8</i> Mutations in Pulmonary Arterial Hypertension. Circulation Genomic and Precision Medicine, 2018, 11, e002087.	3.6	62

#	Article	IF	Citations
55	Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Medicine, 2018, 10, 56.	8.2	112
56	Mutations in BMPR2 are not present in patients with pulmonary hypertension associated with congenital diaphragmatic hernia. Journal of Pediatric Surgery, 2017, 52, 1747-1750.	1.6	3
57	Modified Potts Shunt in an Adult with Idiopathic Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 607-609.	3.2	17
58	The "Central Sport Model― Extracorporeal Membrane Oxygenation Using the Innominate Artery for Smaller Patients as Bridge to Lung Transplantation. ASAIO Journal, 2017, 63, e39-e44.	1.6	58
59	Portopulmonary hypertension in children: a rare but potentially lethal and underâ€recognized disease. Pulmonary Circulation, 2017, 7, 712-718.	1.7	11
60	PVDOMICS. Circulation Research, 2017, 121, 1136-1139.	4.5	113
61	Using Registries to Understand ClinicalÂPractice. Journal of the American College of Cardiology, 2016, 67, 1324-1326.	2.8	3
62	BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respiratory Medicine, the, 2016, 4, 129-137.	10.7	307
63	Characterization of a caveolinâ€1 mutation associated with both pulmonary arterial hypertension and congenital generalized lipodystrophy. Traffic, 2016, 17, 1297-1312.	2.7	48
64	Right ventricular assist device use in ventricular failure due to pulmonary arterial hypertension: Lessons learned. Journal of Heart and Lung Transplantation, 2016, 35, 1272-1274.	0.6	23
65	Chronic Thromboembolic Pulmonary Hypertension, Pregnancy, and a Pulmonary Endarterectomy: A Rare Challenge. Pulmonary Circulation, 2016, 6, 384-388.	1.7	3
66	An Observational Study of Inhaledâ€Treprostinil Respiratoryâ€Related Safety in Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2016, 6, 329-337.	1.7	6
67	Clinical Classification in Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Pulmonary Circulation, 2016, 6, 302-312.	1.7	24
68	Extracorporeal Membrane Oxygenation for Cardiopulmonary Failure During Pregnancy andÂPostpartum. Annals of Thoracic Surgery, 2016, 102, 774-779.	1.3	89
69	Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. Lancet Respiratory Medicine, the, 2016, 4, 281-290.	10.7	20
70	Predicting Peak Oxygen Uptake From the 6-Minute Walk Test in Patients With Pulmonary Hypertension. Journal of Cardiopulmonary Rehabilitation and Prevention, 2016, 36, 203-208.	2.1	17
71	Recommendations for the Use of Inhaled Nitric Oxide Therapy in Premature Newborns with Severe Pulmonary Hypertension. Journal of Pediatrics, 2016, 170, 312-314.	1.8	70
72	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. International Journal of Cardiology, 2016, 202, 52-58.	1.7	37

#	Article	IF	CITATIONS
73	Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. Biomarker Insights, 2015, 10s4, BMI.S29514.	2.5	4
74	Pediatric Pulmonary Hypertension. Circulation, 2015, 132, 2037-2099.	1.6	879
75	Pulmonary hypertension in chronic lung disease of infancy. Current Opinion in Pediatrics, 2015, 27, 177-183.	2.0	15
76	Balloon atrial septostomy in pulmonary arterial hypertension: Effect on survival and associated outcomes. Journal of Heart and Lung Transplantation, 2015, 34, 376-380.	0.6	72
77	Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults. Chest, 2014, 146, 449-475.	0.8	237
78	Effects of Dose and Age on Adverse Events Associated with Tadalafil in the Treatment of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2014, 4, 45-52.	1.7	5
79	Survival Differences in Pediatric Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2014, 63, 2159-2169.	2.8	123
80	Subcutaneous Treprostinil for Pulmonary Hypertension in Chronic Lung Disease of Infancy. Pediatrics, 2014, 134, e274-e278.	2.1	57
81	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	5.6	197
82	Four- and Seven-Year Outcomes of Patients With Congenital Heart Disease–Associated Pulmonary Arterial Hypertension (from the REVEAL Registry). American Journal of Cardiology, 2014, 113, 147-155.	1.6	95
83	Extracorporeal Membrane Oxygenation With Subclavian Artery Cannulation in Awake Patients With Pulmonary Hypertension. ASAIO Journal, 2014, 60, 748-750.	1.6	33
84	Extracorporeal Membrane Oxygenation as a Novel Bridging Strategy for Acute Right Heart Failure in Group 1 Pulmonary Arterial Hypertension. ASAIO Journal, 2014, 60, 129-133.	1.6	74
85	EIF2AK4 Mutations in Pulmonary Capillary Hemangiomatosis. Chest, 2014, 145, 231-236.	0.8	176
86	Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLoS ONE, 2014, 9, e99489.	2.5	107
87	Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatric Pulmonology, 2013, 48, 27-34.	2.0	86
88	Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension. Health and Quality of Life Outcomes, 2013, 11, 31.	2.4	32
89	Successful Treatment of Severe Mechanical Mitral Valve Thrombosis With Tissue Plasminogen Activator in a 7-Month-Old Infant. Pediatric Cardiology, 2013, 34, 1903-1907.	1.3	1
90	A Novel Channelopathy in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 351-361.	27.0	412

#	Article	IF	CITATIONS
91	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Current Pediatrics Reports, 2013, 1, 92-101.	4.0	2
92	Pediatric Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D117-D126.	2.8	451
93	Implications of the U.S. Food and Drug Administration Warning against the Use of Sildenafil for the Treatment of Pediatric Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 572-575.	5.6	99
94	Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Clinics in Chest Medicine, 2013, 34, 707-717.	2.1	10
95	Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Cardiovascular Therapeutics, 2013, 31, 38-44.	2.5	29
96	Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nature Genetics, 2013, 45, 518-521.	21.4	93
97	Clinical Trials in Neonates and Children: Report of the Pulmonary Hypertension Academic Research Consortium Pediatric Advisory Committee. Pulmonary Circulation, 2013, 3, 252-266.	1.7	35
98	Updating Clinical Endpoint Definitions. Pulmonary Circulation, 2013, 3, 206-216.	1.7	22
99	The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica, 2013, 98, 464-472.	3.5	170
100	Upperâ€Body Extracorporeal Membrane Oxygenation as a Strategy in Decompensated Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 432-435.	1.7	69
101	Safety of Cardiac Catheterization at a Center Specializing in the Care of Patients with Pulmonary Arterial Hypertension. Pulmonary Circulation, 2013, 3, 831-839.	1.7	54
102	Targeted Pulmonary Arterial Hypertension Therapies and a Combined Medical-Surgical Approach for Congenital Heart Disease Patients. Advances in Pulmonary Hypertension, 2013, 11, 183-188.	0.1	0
103	Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension. Circulation: Cardiovascular Genetics, 2012, 5, 336-343.	5.1	333
104	Pediatric Pulmonary Arterial Hypertension and Hyperthyroidism: A Potentially Fatal Combination. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2217-2222.	3.6	15
105	Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 1546-1550.	1.6	34
106	Effectiveness and Safety of Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Children. American Journal of Cardiology, 2012, 110, 1704-1709.	1.6	62
107	Congenital heart disease and pulmonary hypertension: pharmacology and feasibility of late surgery. Progress in Cardiovascular Diseases, 2012, 55, 128-133.	3.1	34
108	Pulmonary hypertension in children with sickle cell disease. Expert Review of Respiratory Medicine, 2011, 5, 233-243.	2.5	12

#	Article	IF	Citations
109	Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension. Circulation, 2011, 123, 2985-2993.	1.6	127
110	Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood, 2011, 118, 855-864.	1.4	210
111	Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease. American Journal of Cardiology, 2011, 107, 1381-1385.	1.6	98
112	Common Atrium and Pulmonary Vascular Disease. Pediatric Cardiology, 2011, 32, 595-598.	1.3	7
113	Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation, 2011, 124, 1452-1460.	1.6	124
114	Effectiveness of Transition from Intravenous Epoprostenol to Oral/Inhaled Targeted Pulmonary Arterial Hypertension Therapy in Pediatric Idiopathic and Familial Pulmonary Arterial Hypertension. American Journal of Cardiology, 2010, 105, 1485-1489.	1.6	38
115	Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings. American Journal of Cardiology, 2010, 106, 1332-1338.	1.6	101
116	Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy, 2010, 11, 127-132.	1.8	36
117	Non-congenital heart disease associated pediatric pulmonary arterial hypertension. Progress in Pediatric Cardiology, 2009, 27, 13-23.	0.4	20
118	Pulmonary arterial hypertension in children: A Medical Update. Indian Journal of Pediatrics, 2009, 76, 77-81.	0.8	10
119	Dopplerâ€defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. British Journal of Haematology, 2009, 146, 437-441.	2.5	45
120	Polymorphism in the Angiotensin II Type 1 Receptor (AGTR1) is Associated With Age at Diagnosis in Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2009, 28, 373-379.	0.6	34
121	Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension. Chest, 2009, 135, 752-759.	0.8	116
122	Clinical Implications of Determining BMPR2 Mutation Status in a Large Cohort of Children and Adults With Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2008, 27, 668-674.	0.6	157
123	Plasma serotonin levels are normal in pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2008, 21, 112-114.	2.6	25
124	Pulmonary arterial hypertension in children: a medical update. Current Opinion in Pediatrics, 2008, 20, 288-293.	2.0	28
125	Platelet-Derived Growth Factor Is Increased in Pulmonary Capillary Hemangiomatosis. Chest, 2007, 131, 850-855.	0.8	38
126	The effect of atrial septostomy on the concentration of brain-type natriuretic peptide in patients with idiopathic pulmonary arterial hypertension. Cardiology in the Young, 2007, 17, 557-559.	0.8	23

#	Article	IF	Citations
127	Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2006, 19, 370-374.	2.6	59
128	Emerging treatments for pulmonary arterial hypertension. Expert Opinion on Emerging Drugs, 2006, 11 , 609-619.	2.4	6
129	A SECONDARY CARE PERSPECTIVE ON THE STEPPING-DOWN OF INHALED CORTICOSTEROID THERAPY IN PATIENTS WITH STABLE ASTHMA. Chest, 2005, 128, 242S.	0.8	4
130	Pulmonary Capillary Hemangiomatosis. Chest, 2005, 128, 575S-576S.	0.8	18
131	Idiopathic pulmonary arterial hypertension in children. Current Opinion in Pediatrics, 2005, 17, 372-380.	2.0	39
132	von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension. Chest, 2005, 128, 2355-2362.	0.8	75
133	New predictors of outcome in idiopathic pulmonary arterial hypertension. American Journal of Cardiology, 2005, 95, 199-203.	1.6	227
134	Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2005, 46, 697-704.	2.8	245
135	Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension. Circulation, 2004, 110, 660-665.	1.6	223
136	Pulmonary arterial hypertension in children. Pediatric Pulmonology, 2004, 38, 2-22.	2.0	134
137	Identical Twins With Primary Pulmonary Hypertension. Chest, 2004, 125, 1157-1159.	0.8	3
138	Eisenmenger syndrome in ventricular septal defect patients. Progress in Pediatric Cardiology, 2001, 14, 175-180.	0.4	2
139	Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension. Expert Opinion on Investigational Drugs, 2001, 10, 811-823.	4.1	1
140	Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart Defects. Circulation, 1999, 99, 1858-1865.	1.6	464
141	Late Left Ventricular Function After Surgery for Children With Chronic Symptomatic Mitral Regurgitation. Circulation, 1997, 96, 4280-4285.	1.6	27
142	Four-Dimensional Flow Imaging to Evaluate Shunt Flow in a Unidirectional Valved Potts Shunt. Circulation: Cardiovascular Imaging, 0, , .	2.6	0